9. EVALUATE OF COMBINED METRONIDAZOLE PLUS IVERMECTINE EFFICACY IN THE TREATMENT FOR HUMAN DEMODICOSIS
Main Article Content
Abstract
Objective: To evaluate of combined metronidazole plus ivermectine (MTZ + IVM) efficacy in treatment of human demodicosis.
Methods: A non-randomized uncontrolled trial design for evaluate of combined MTZ + IVM regimen efficacy in treatment of human demodicosis.
Results: The efficacy of combined MTZ + IVM regimen in the treatment for 80 enrolled demodicosis patients showed that significantly reduced of itching, stinging, crawling ants, and erythema/ red skin, and skin scales at points of before and after one and two months intervention; Demodex density reduced from 8.8±4.5 to 1.5 ± 1.1 and 0.6 ± 0.2/ microscope field after 1 and 2 months, respectively. The proportion of high response, moderate response, and low response were 80.3% and 88.7%; 13.2% and 5.6%; 3.9% and 1.4% in one and two months post-treatment, respectively. Non-response or treatment failure at one and two months post-treatment were 2.6% and 4.3%. Some advert events in the first ten days since drugs taken included of itching, skin burning 2 (2.5%), fatigue 6 (7.5%), dizziness 2 (2.5%), abdomen pain 3 (3.8%), nausea 3 (3.8%).
Conclusions:Combined MTZ + IVM regimen has high efficacy 80.3% and 88,7% at one and two months post-treatment, respectively.
Article Details
Keywords
Demodicosis, combined metronidazole ivermectine, efficacy
References
các bệnh ký sinh trùng, Vol. 125, Số 5, tr.30-40, 2023.
[9] Trần Cẩm Vân (2023). So sánh kết quả điều trị viêm da do Demodex bằng uống ivermectin kết hợp bôi metronidazol 1% với liệu pháp uống và bôi metronidazol kết hợp. Y học cộng đồng, Số Chuyên đề ký sinh trùng, Số 76, tr. 198-203.
[10] Avila MY, Martinez-Pulgarin DF, Rizo Madrid C et al., (2021). Topical ivermectin- metronidazole gel therapy in the treatment of blepharitiscaused by Demodex: A randomized clinical trial. Cont Lens Anterior Eye;44(3):101326.
[11] Gonzalez P, Gonzalez FA, Ueno K et al., (2012). Ivermectin in human medicine: An overview of the current status of its clinical applications.Curr Pharm Biotechnol, 13(6): 1103-9.
[12] Jiahua Li, Erdong Wei, Amin Reisinger, Markus Reinholz (2023). Comparison of different anti-Demodex strategies: A systematic review and meta-analysis. Dermatology, 239(1):12-31.
[13] KashifSiddiqui, LindaSteinGold, JapinderGill (2016). The efficacy, safety, and tolerability of ivermectin compared with current topical treatments for the inflammatory lesions of rosacea: A network meta-analysis. Springer Plus (2016); 5:1151
[14] NS Lam, X Long , RC Griffin, JCG Doery, F Lu (2019). Human demodicidosis and the current treatment options. Hong Kong J. Dermatol. Venereol. (26):10-17
[15] McClellan KJ, Noble Set al.,(2000). Topical metronidazole: A review of its use in rosacea. Am J Clin Dermatol,1(3):191-9.
[16] Salem DA, El-Shazly A, Nabih N, El-Bayoumy Yet al., (2013). Evaluation of the efficacy of oral ivermectin in comparison with ivermectin-metronidazole combined therapy in the treatment of ocular and skin lesions of Demodex folliculorum. Int J Infect Dis, 17(5):343-347.
[17] Taieb A, Ortonne JP et al., (2015). Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: A randomized, investigator-blinded trial.Br J Dermatol, 172(4):1103-10.